Research Article

Bacterial versus human thymidylate synthase: Kinetics and functionality

Zahidul Islam*, Ilya Gurevic, Timothy S. Strutzenberg, Ananda K. Ghosh, Tasnia Iqbal, Amnon Kohen*

Department of Chemistry, The University of Iowa, Iowa City, IA, United States of America

* These authors contributed equally to this work.

α Current address: Institute for Quantitative Biosciences (QB3), University of California-Berkeley, Berkeley, CA, United States of America

β Current address: Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL, United States of America

* zahid@berkeley.edu (ZI); amnon-kohen@uiowa.edu (AK)

Abstract

Thymidylate Synthase (TSase) is a highly conserved enzyme that catalyzes the production of the DNA building block thymidylate. Structurally, functionally and mechanistically, bacterial and mammalian TSases share remarkable similarities. Because of this closeness, bacterial enzymes have long been used as model systems for human TSase. Furthermore, while TSase inhibitors have long served as chemotherapeutic drugs, no TSase inhibitor serves as an antibiotic. Despite their high resemblance, the mammalian TSases are distinct in a few known aspects, such as having a N-terminal tail and two insertions in the primary sequence and active/inactive conformations. Here, we aim to comprehensively characterize human (hs) TSase and delineate its contrasts and the similarities to the well-studied Escherichia coli (ec) TSase. We found that, in contrast to ecTSase, Mg2+ does not enhance reaction rates for hsTSase. The temperature dependence of intrinsic kinetic isotope effects (KIEs), on the other hand, suggests that Mg2+ has little or no impact on the transition state of hydride transfer in either enzyme, and that the transition state for the hydride transfer in hsTSase is looser than in ecTSase. Additionally, the substrates’ binding order is strictly ordered for ecTSase but slightly less ordered for hsTSase. The observed kinetic and functional differences between bacterial and human enzymes may aid in the development of antibiotic drugs with reduced toxicity.

Introduction

The last committed step in the de novo synthesis of thymidylate (2’-deoxythymidine-5’-monophosphate, dTMP) in most living organisms is catalyzed by the enzyme thymidylate synthase (TSase). Suppression of TSase activity in cells causes a deficiency in the intracellular concentration of thymidylate, bringing DNA reproduction to a halt and thus causing death to cells [1]. The participation of TSase in the biosynthesis of DNA renders this enzyme a suitable target for anticancer drugs [2, 3]. Two well-known drugs, 5-fluorouracil and raltitrexed, that target...
TSase are prescribed for the treatment of a wide variety of cancers including colorectal, breast and pancreatic tumors [2, 3]. Antibacterial drugs targeting TSase, however, are not in use, in part due to the known structural and functional similarities between the bacterial and human enzymes.

In the production of dTMP, TSase requires a cofactor, methylene tetrahydrofolate (MTHF), that donates a methylene and a hydride in two separate mechanistic steps; thus, a net methyl group substitutes the C5 hydrogen of the substrate 2′-deoxyuridine-5′-monophosphate (dUMP) (Fig 1) [1, 4]. In the mechanism of ecTSase, an active-site cysteine makes a nucleophilic attack at the C6 of dUMP, forming a covalent TSase-dUMP enolate (step 2 in Fig 1). The enolate attacks the pre-activated, iminium form of MTHF, leading to the formation of a covalently bonded enzyme-substrate-cofactor ternary complex, TSase-dUMP-MTHF (compound C in Fig 1). Abstraction of the C5 proton by an active site general base causes dissociation of MTHF as tetrahydrofolate (THF) and formation of an exocyclic methylene intermediate (compound D in Fig 1). Finally, a hydride from THF is transferred to the C7 of intermediate D, accounting for the products dTMP and dihydrofolate (DHF).

TSase is one of the most highly conserved enzymes known—from the very primitive organisms to humans. E. coli (ec) and human (hs) TSase share 46% and 60% sequence identity and similarity, respectively (Fig 2, panel A). Residues in the active site, substrate binding region, and many of the remote residues are also found to be highly conserved across the spectrum of life that encodes the thyA gene [5, 6]. Both secondary and tertiary structures of ec and hs TSase align quite well with each other (Fig 2, panel B). Because of these similarities in sequences, structures and functions, bacterial TSase has long been used as a model system for drug design targeting the human enzyme.

However, despite structural and functional similarities between bacterial and human TSase, the mammalian TSases are distinct in a few aspects. First of all, mammalian TSases have evolved to incorporate multiple insertions into different regions of the polypeptide chain: an extension of the N-terminus by 29 residues and an insertion of 12 and 8 residues at positions 117 and 146, respectively (positions mentioned refer to the hsTSase sequence unless otherwise stated). A contrast between bacterial and human TSase is also noted in protein conformations [7]. While ecTSase crystallizes only in the closed conformation both in the presence and the absence of ligands, in crystal structures of hsTSase the loop comprising residues 181–197, which includes the catalytic nucleophile cysteine 195, is rotated 180˚ out of the active site in its unliganded state. This is referred to as the inactive conformation. The binding of substrates or their analogues induces a conformational change across the protein that rotates this loop towards the active site, transforming the enzyme into an architecture poised for catalysis. Conformational switching causes other structural changes as well, such as bringing the loop comprising residues 107–128, which includes one of the eukaryotic insertions, from a disordered to an ordered structure as the enzyme goes from its inactive to its active configuration [7]. It has long been known that Mg2+ enhances the turnover number of bacterial TSase; however, this effect has not been tested for mammalian TSases [8, 9]. To further explore discrepancies between microbial and hsTSase, a thorough kinetic and mechanistic investigation of hsTSase is warranted. A more detailed characterization of hsTSase might reveal crucial properties, different from bacterial ones, that would aid in the design of non-toxic antibacterial drugs [5].

Exploitation of fine differences between the E. coli and human enzymes has precedent [5]. Namely, one report featured the development of dansyl hydrazine, dansyl tyrosine and didansyl tyrosine as specific folate-competitive inhibitors of human, Lactobacillus casei and E. coli TSases, respectively, with modest potency (>1 μM) but approximately 1–2 orders of magnitude of selectivity. This suggests that additional discrete properties of hsTSase could be utilized for designing more potent, more selective finely-tuned new chemotherapeutic drugs.
TSase exerts a tight control over its intracellular expression during cell cycles. This enzyme binds its own mRNA, repressing its translation. Thereby, the organism achieves a negative autoregulation [10–13]. The apo state of TSase promotes the formation of protein-mRNA complex. For positive autoregulation, binding of substrates or substrate analogues disrupts the formation of TSase-mRNA, causing translational derepression and synthesis of more protein. Translational autoregulation of protein synthesis is prevalent in bacteria, but such feedback regulation by binding to mRNA is rare in eukaryotes [10]. In humans, the TSase system represents the first reported instance of such translational autoregulation [10]. Control over expression and function of TSase may also be achieved by posttranslational modifications [14]. In contrast to the bacterial one, mammalian TSases are reportedly known to undergo certain posttranslational modifications in certain cell lines under certain conditions [14]. Those modifications could include methylation, phosphorylation [14] and/or acetylation of the N-terminal methionine [15]. It was reported that hsTSase could under particular circumstances have methylated glutamates and phosphorylation at serine. However, neither the modification sites nor the functional effect of those modifications, nor the conditions under which these forms are generated, have been unequivocally documented [14, 16, 17]. While a plethora of kinetic,
structural and mechanistic studies are available on bacterial TSase [1, 4, 8, 18–22], mammalian TSase lacks such deep interrogations. Here we aim at a more comprehensive characterization of recombinant hsTSase. We report multiple kinetic investigations with and without Mg\(^{2+}\), substrate binding order studies, and assessment of intrinsic KIEs and their temperature dependence for the proton and hydride transfer (steps 4 and 5 in Fig 1). The contrasts and similarities in function and kinetics between ec and hs TSase are presented and discussed. The KIE studies provide a sense of the active site architecture. In general, KIE results lead to information on distance considerations that guide medicinal chemists toward atomic replacement and/or spacers like methylene groups. There is precedent for the design of a femtomolar transition state analogue inhibitor for the enzyme purine nucleoside phosphorylase based in large part on the determination of KIEs.[23, 24] For instance, if the human TSase were found to be larger, the active site could be expanded by atomic replacement, i.e. including a larger atom; for example, N5 of the folate could be replaced with a phosphorus atom in a non-reactive MTHF analog to make the ground state of the resulting ternary complex more like the transition state for hydride transfer. The non-reactive MTHF analog inhibitor for E. coli TSase could replace N5 with an atom of similar size (for example, carbon).

Materials and methods

Materials and instruments

Ni-NTA Superflow resin was purchased from Qiagen. GE Healthcare Life Sciences was the source of the PD-10 desalting columns filled with Sephadex G-25 resin. LB powder was purchased from Research Products International, Inc. \([5-\text{H}]-\text{dUMP, specific radioactivity} \approx 14 \text{Ci/mmol (for proton abstraction KIEs)}\) and \([2-\text{C}]-\text{dUMP, specific radioactivity} \approx 53 \text{mCi/}

Protein expression and purification

Vector pQE80L containing the TYMS gene was a generous gift from Professor M. Paola Costi and Reggio Emilia, University of Modena, Italy. We sub-cloned the gene into pET28a(+) containing a thrombin cleavable polyhistidine. We inserted the TSase gene between NdeI and BamH1 restriction sites of pET28a(+) plasmid. The sub-cloned pET28a(+) encoding His\(_{6}\)-hsTSase and kanamycin resistance as a selection marker was transformed into E. coli BL21 (DE3) cells. Plasmid was extracted from several colonies and sequenced to verify proper transformation, and these colonies were propagated and preserved as 40% glycerol stocks at -80°C. After overnight growth at 37°C of a primary culture of ~50 mL supplemented with kanamycin at a final concentration of 40 mg/L, inoculation into four flasks of 1.5 L bulk culture LB media in each containing kanamycin at a final concentration of 40 mg/L was performed at a 1:150 ratio. After growth to an O.D. at 600 nm of approximately 0.8, IPTG was added to a final concentration of 1 mM, initiating overexpression of the target protein overnight (~12 hrs). After
harvesting cells by centrifugation at ~5000 rpm for 30 minutes at 4°C, the pellets were frozen at -80°C until further processing; ~2 g of cells were obtained per liter of bulk culture.

Cell pellets—typically from 3 L of bulk culture—were resuspended in 4 mL of resuspension buffer (25 mM potassium phosphate, 30 mM NaCl, pH = 7.5) per gram of original cell mass with continuous stirring; this and all subsequent steps were performed at 4°C. Once the pellet was resuspended (~30 minutes), the cells were lysed by passing through the French Press apparatus twice. The lysate was centrifuged at 15,000 rpm for 30 min, after which the supernatant was retained and the cell debris discarded. The lysate was subjected to gentle rocking with ~ 1 mL of Ni-NTA Superflow resin per gram of original cell mass for one hour. The mixture was applied to a column pre-packed with ~0.5 mL of Ni-NTA Superflow resin per gram of original cell mass and pre-equilibrated in wash buffer (50 mM potassium phosphate, 25 mM imidazole, pH 7.5). After collecting the flow-through, five column volumes (CV) of wash buffer were passed through the column, collecting 5 mL fractions and testing them by visual Bradford assay for protein content until no noticeable protein remained. Next, 5 CV of elution buffer (50 mM potassium phosphate, 250 mM imidazole, pH 7.5) were passed through the column, and eluent was collected in 1–3 mL fractions, until no protein was evident in the eluent. The eluent was then buffer-exchanged into 25 mM potassium phosphate, 30 mM NaCl, pH 7.5, by using a PD-10 desalting column. The concentration of protein in the resulting solution was measured by Nanodrop using $\varepsilon_{280} = 43,130 \text{ M}^{-1} \text{ cm}^{-1}$.

In order to remove the thrombin-cleavable hexahistidine tag, the solution of $\text{hSTase}$ from the previous step and thrombin were combined in a final concentration of 0.75 U thrombin/(mg protein), in thrombin cleavage buffer provided by GE Healthcare. The concentration of $\text{hSTase}$ was approximately 5 mg/ml and the mixture was incubated at 4°C with rocking overnight (~12 hrs). A Ni-NTA column was packed and equilibrated in wash buffer (composition as above). The solution was applied to the column; flow-through, containing the target, tag-free $\text{hSTase}$, was collected and saved. Next, ~5 column volumes (CV) of wash buffer were passed through the column until the visual Bradford assay indicated no protein in the wash. The flow-through was concentrated via Amicon 10 kDa cutoff concentrators and buffer-exchanged into 25 mM potassium phosphate pH 7.5; then ethylene glycol was added to 10% of the volume. The final concentration of enzyme was around 300 μM, as determined by Nanodrop using $\varepsilon_{280} = 43,130 \text{ M}^{-1} \text{ cm}^{-1}$ and was stored in small (~50 μl) aliquots at -80°C. The presence of the tag-free $\text{hSTase}$ was confirmed by MALDI-TOF mass spectrometry.

**Steady-state parameters for WT $\text{hSTase}$ with and without Mg$^{2+}$**

Stock solutions of 10 mM dUMP in 100 mM tris, pH 7.5, and 10 mM MTHF in ascorbate-citrate buffer with 10 mM HCHO and 4 mM TCEP were prepared. Standardization of the concentration of the MTHF stock was performed by combining a known volume with excess dUMP in reaction buffer (100 mM tris pH 7.5 buffer, with 1 mM tris(carboxyethyl) phosphine (TCEP) to prevent oxidation of cysteines, 50 mM MgCl$_2$, and 7 mM HCHO) in a quartz cuvette of 1 cm pathlength in the HP UV-vis spectrophotometer. Next, the initial $A_{340}$ was noted, and enzyme was added to initiate the reaction followed by thorough mixing. The difference in $A_{340}$ between the initial and plateau levels was converted to concentration present initially using $\Delta A_{340, \text{MTHF-DHF}} = 6,400 \text{ M}^{-1} \text{ cm}^{-1}$ [26]. The enzyme concentration was quantified by diluting the enzyme stock in reaction buffer and using $\varepsilon_{280} = 43,130 \text{ M}^{-1} \text{ cm}^{-1}$ as determined from web.expasy.org/protparam/.
Steady-state kinetics were studied by using reactions in the wells of a 96-well plate in an Epoch plate reader at approximately 22˚C. The total reaction volume in each well was 300 μL, with 150 μL of 2x assay buffer (200 mM tris pH 7.5, 2 mM TCEP, 14 mM HCHO), 30 μL of dUMP solution at the appropriate concentration, 30 μL of MTHF solution at the appropriate concentration, 30 μL of ddH₂O or of 0.5 M MgCl₂ depending on the experimental condition, 30 μL of ddH₂O and initiated with 30 μL of 150 nM hsTSase. In order to determine the appropriate pathlength, reactions were initiated with varied [MTHF] and no dUMP. The steady \( A_{340} \) was divided by the concentration of MTHF and by the previously reported \( \varepsilon_{340,MTHF} = 1,010 \text{ M}^{-1} \text{ cm}^{-1} \) [27] to find \( b = 0.87 \text{ cm} \). Each run included three rows of 8 wells, initiated at the same time; each condition was repeated in triplicate. At a final concentration of 100 μM MTHF, dUMP was varied from 1 μM to 100 μM final concentration. At a final concentration of 100 μM dUMP, MTHF was varied from 2 μM to 500 μM. Scans were performed every few seconds over the course of 15 minutes. Linear regions over the first few minutes of the experiment were selected for analysis and fit to a line, whose slope was divided by \( \Delta \varepsilon_{340,MTHF-DHF} = 6,400 \text{ M}^{-1} \text{ cm}^{-1} \) [26] and the pathlength to find the initial velocity in concentration per second. Goodness of fit statistics were favorable, \( R^2 > 0.9, \text{ RSD} < 10\% \). These initial velocity values were then divided by enzyme concentration.

For the data analysis, the rates (divided by the total enzyme) for all three replicates were included in performing the fitting. For fixed MTHF and varied dUMP, a simple Michaelis-Menten model was used:

\[
\frac{V}{[E]_{t}} = \frac{k_{cat}[dUMP]}{K_{m,dUMP} + [dUMP]}
\]

Here, \( V \) refers to the initial velocity, \([E]_{t}\) is the total enzyme concentration, \( K_{m,dUMP} \) is the Michaelis constant for dUMP and \( k_{cat} \) is the enzyme’s turnover number. However, the studies with fixed dUMP and varied MTHF were fitted to a model that accounts for substrate inhibition by MTHF, with the choice of Hill coefficient = 1 [8]:

\[
\frac{V}{[E]_{t}} = \frac{k_{cat}[S]}{K_{m,MTHF} + [S](1 + \frac{S}{K_{S}})}
\]

Here, \( V \) refers to the initial velocity, \([E]_{t}\) is the total enzyme concentration, \( K_{m,MTHF} \) is the Michaelis constant for MTHF, \( k_{cat} \) is the enzyme’s turnover number and \( K_{S} \) is the substrate inhibition constant for MTHF. Although the fit was to all of the replicates, only the means and standard deviations at each condition are shown in the plots along with the fitted curve.

**Proton abstraction H/T kinetic isotope effects for hsTSase while varying [MTHF]**

Reaction mixtures were prepared in 100 mM tris pH 7.5 buffer, with 1 mM TCEP (antioxidant), 50 mM MgCl₂, and 7 mM HCHO. A mixture of [5-\(^3\)H]-dUMP and [2-\(^14\)C]-dUMP was prepared such that the ratio of \(^3\)H:\(^14\)C was between 5 and 9, as the lower average energy of \( \beta \) particles from \(^3\)H than \(^14\)C necessitates higher tritium radioactivity for accuracy of LSC counting. The total [dUMP] was approximately 3 μM, while [MTHF]–present in excess in all cases–was varied, ranging from the low μM to the mM range. The pH of each mixture was adjusted at 25˚C. There was ~ 500 μL of reaction mixture total, with approximately 150 kilodisintegrations per minute (kdpm) \(^3\)H and 20 kdpm \(^14\)C per ~ 30–40 μL aliquot. A sample of ~ 30–40 μL representing \( t_{zero} \) in order to identify the tritium originally in water, was taken for each reaction. Then enzyme, diluted in 100 mM tris at pH = 7.5, was added to ~10% of the final volume.
The final enzyme concentrations were typically in the 10–50 nM range. Aliquots were mixed with ~ 10 μL of 5-fluoro dUMP inhibitor solution (at least 10-fold molar excess over dUMP) and frozen in liquid nitrogen at times that correspond to 20–80% fractional conversion (f) as assessed by 14C radioactivity (100% = (14C-dTMP)/(14C-dUMP + 14C-dUMP)) upon HPLC separation. Approximately ten samples were taken over the course of the reaction (time points, usually within an hour of initiating the reaction); after the last one, a large concentration of WT hsTSase was added, and the mixture was incubated an additional 30–45 min to ensure no starting materials remained (infinity points). Ratios of tritium in water–corrected for initial tritium in water–to 14C in dTMP, 3H in water 14C in dTMP, at time t (R_t) and infinity (R_∞) were computed, with at least four time points and two infinities per concentration of MTHF. The relevant values of KIE_{obs} = \frac{\ln(1-f)}{\ln(1-f)} were extracted [28]. The observed KIEs in this one-pot, competitive measurement are the ratio of the catalytic efficiencies \( \frac{k_{cat, D}}{k_{cat, T}} \) for the light isotopologue of the substrate over the heavy isotopologue of the substrate.

**Proton abstraction D/T and intrinsic kinetic isotope effects for hsTSase**

In general, procedures here closely followed those previously published [22]. The competitive D/T KIE experiment was performed at the same concentrations of substrates (~ 3 μM total [dUMP] and ~ 4 μM [MTHF]), similar concentrations of enzyme and in the same manner as the H/T experiment. The labeled nucleotides for the D/T experiment–[5-3H]-dUMP and [5-2H, 2-14C]-dUMP–were prepared as reported previously [29, 30]. The analysis and interpretation of our data tracks with published reviews [31, 32]. All possible combinations of observed KIEs were employed to obtain intrinsic KIEs according to the Northrop equation [33]

\[
\frac{1}{KIE_{HT}^{int}} - 1 = \frac{1}{KIE_{HT}^{obs}} - 1 = \frac{1}{(KIE_{HT}^{int})^{0.3}} - 1
\]

This equation, in which KIE_{HT}^{int} is the only unknown, has no analytical solution but can be solved via numerical methods (an online version is found at https://chem.uiowa.edu/kohen-research-group/calculation-intrinsic-isotope-effects) [28, 33]. A plot of KIE_{HT}^{int} versus 1/T was generated and fitted, using Kaleidagraph 4.5.3 software, to the Arrhenius equation:

\[
KIE_{HT}^{int} = \frac{k_H}{k_T} = \frac{A_H}{A_T} \exp\left(-\frac{\Delta E_{a(T-H)}}{RT}\right)
\]

where ΔE_{a(T-H)} and A_H/A_T represent isotope effects on the activation energy and on the pre-exponential factor, respectively, and H and T denote hydrogen and tritium, respectively. All the intrinsic KIE values were employed to obtain the fitting parameters, but only average intrinsic KIEs at each temperature are depicted in the graph.

**Hydride transfer kinetic isotope effects**

In general, procedures here followed closely along the lines of those previously published [8]. Reaction mixtures were again in 100 mM tris pH 7.5 buffer, with 1 mM TCEP to prevent oxidation of cysteines, 50 mM MgCl₂, and 7 mM HCHO. In buffer without Mg²⁺, a final concentration of 1 mM EDTA was used to prevent adventitious Mg²⁺ from exerting a confounding effect on our results. For H vs. T competitive experiments, mixtures of (R)-6-[3H]-MTHF + (R)-6-[1H]-MTHF + [14C]-dUMP were prepared, while for D vs. T competitive experiments, mixtures of (R)-6-[3H]-MTHF + (R)-6-[2H]-MTHF + [14C]-dUMP were prepared, such that the ratio of 3H:14C was between 4 and 9. The total [MTHF] was ~ 80–120 μM, while total
Mg$^{2+}$ enhances rates of ecTSase but not hsTSase. Previous studies reported that Mg$^{2+}$ accelerates the rate of ecTSase by seven-fold and increases the Michaelis constant ($K_M$) for dUMP by ~5-fold at 25°C although $K_M$ reflects more steps than just binding [8, 9]. MTHF substrate-inhibition is known for ecTSase because of an alternative unproductive binding mode of the cofactor [18, 34]. The presence of Mg$^{2+}$ affects the cooperativity in MTHF binding, suggesting Mg$^{2+}$ mediates the interaction between MTHF and the ecTSase [8]. To examine the effect of Mg$^{2+}$ on hsTSase the same steady state parameters were measured in the absence and presence of 50 mM Mg$^{2+}$—the same concentration used in the studies for ecTSase. In contrast to bacterial TSase, the steady-state experiments showed no effect of Mg$^{2+}$ on hsTSase (Table 1). Michaelis-Menten plots appear in S1 and S2 Figs. The hsTSase measurements compare favorably with ref [35]. The catalytic efficiency of mammalian TSase with respect to dUMP was found to be about 10-fold lower than that for bacterial TSase irrespective of Mg$^{2+}$. Like ecTSase, hsTSase exhibits MTHF substrate-inhibition, but in contrast to ecTSase, this was not affected by Mg$^{2+}$. Thus, it seems that in contrast to ecTSase the presence of Mg$^{2+}$ had little or no influence on steady state parameters for hsTSase. In ecTSase, Mg$^{2+}$ was found to bind between the glutamate tail of MTHF and the surface of the protein, appearing to thereby mediate a hydrogen bond network that extends from its binding region (residues 76 to 93 in ecTSase) to the active site of the protein [8]. This communication of Mg$^{2+}$ through the H-bond network to the catalytic site might contribute to the rate enhancements observed for ecTSase. However, the residues that constitute the Mg$^{2+}$ binding region in ec are not conserved in...
hsTSase; therefore, Mg\textsuperscript{2+} may not have an opportunity to bind the protein at the corresponding site of hsTSase.

**Mg\textsuperscript{2+} has no impact on the transition state structure of hydride transfer.** Previous studies reported that in the absence of Mg\textsuperscript{2+} the hydride transfer in ecTSase is rate-limiting on both the first order (\(k_{cat}\)) and the second order rate constants (\(k_{cat}/K_m\)) [18, 36]. Since Mg\textsuperscript{2+} accelerates the turnover rate and makes the hydride transfer non-rate-limiting, it seems that Mg\textsuperscript{2+} contributes to the activation of hydride transfer in ecTSase. For hsTSase, on the other hand, Mg\textsuperscript{2+} does not have any impact on the turnover number. However, to check if Mg\textsuperscript{2+} has any impact on the organization of the active site for the hydride transfer, we examined the intrinsic kinetic isotope effect (KIE) on this step with and without Mg\textsuperscript{2+} by following the same competitive method used for ecTSase. KIE is a useful probe for assessing a specific kinetic step in the cascade of physical and chemical events [32, 37–39]. We found that Mg\textsuperscript{2+} has a marginal effect on the observed KIEs in hsTSase, but no impact on its intrinsic value (Table 2). The lack of change in intrinsic KIEs indicates that Mg\textsuperscript{2+} has no influence on the transition state structure of hydride transfer in both bacterial and human TSases. Taken together, although ec and hs TSase are structurally and mechanistically very much alike, the function and kinetic parameters of only ecTSase seem to be affected by Mg\textsuperscript{2+}.

**Substrate binding order in E. coli vs. human TSase.** To convert dUMP to dTMP, TSase requires MTHF that provides a net methyl. Binding of the dUMP to ecTSase prompts binding of MTHF to the protein, leading to the formation of the ternary complex [40]. This sequence is likely facilitated by the fact that ecTSase maintains a very strict substrate-binding order: dUMP is the first to bind, followed by MTHF [19].

### Table 1. Steady-state kinetic parameters of ec and hs TSase in the presence and absence of Mg\textsuperscript{2+} (S1 and S2 Figs).

| Parameter                   | Enzyme | w Mg\textsuperscript{2+} | w/o Mg\textsuperscript{2+} |
|-----------------------------|--------|---------------------------|----------------------------|
| \(k_{cat}\) (s\textsuperscript{-1}) | ec     | 8.7 ± 0.2                 | 1.32 ± 0.02                |
|                             | hs     | 0.54 ± 0.03               | 0.52 ± 0.02                |
| \(K_m\)\textsubscript{MTHF} (μM) | ec     | 15 ± 1                    | 17 ± 2                     |
|                             | hs     | 4.5 ± 0.8                 | 2.9 ± 0.4                  |
| \(K_m\)\textsubscript{dUMP} (μM) | ec     | 2.4 ± 0.2                 | 0.5 ± 0.1                  |
|                             | hs     | 2.5 ± 0.8                 | 4.2 ± 0.8                  |
| \(k_{cat}/K_m\)\textsubscript{dUMP} (s\textsuperscript{-1}μM\textsuperscript{-1}) | ec | 3.6 ± 0.3 | 2.6 ± 0.6 |
|                             | hs     | 0.22 ± 0.07               | 0.12 ± 0.02                |

\(k_{cat}/K_m\)\textsubscript{MTHF} (s\textsuperscript{-1}μM\textsuperscript{-1})

| ec | 0.58 ± 0.04 | 0.08 ± 0.01 |
| hs | 0.12 ± 0.02 | 0.18 ± 0.03 |

\*ref [8, 18].

https://doi.org/10.1371/journal.pone.0196506.t001

### Table 2. Observed and intrinsic KIEs of ec and hs TSase in presence and absence of Mg\textsuperscript{2+}.

| Parameter                     | Enzyme | w Mg\textsuperscript{2+} | w/o Mg\textsuperscript{2+} |
|-------------------------------|--------|---------------------------|----------------------------|
| KIE\textsubscript{obs} (H/T)  | ec     | 4.14 ± 0.02               | 7.07 ± 0.03                |
|                              | hs     | 3.05 ± 0.03               | 3.19 ± 0.03                |
| KIE\textsubscript{obs} (D/T)  | ec     | 1.65 ± 0.01               | 1.81 ± 0.04                |
|                              | hs     | 1.61 ± 0.02               | 1.64 ± 0.01                |
| Intrinsic KIE (H/T)           | ec     | 7.4 ± 0.9                 | 7.4 ± 0.5                  |
|                              | hs     | 11.0 ± 0.9                | 11.6 ± 0.8                 |

\*from ref [8, 18].

https://doi.org/10.1371/journal.pone.0196506.t002
To test whether this is also true for hsTSase we measured the effect of MTHF concentration on the observed KIEs measured with isotopically labeled dUMP as reported for the ecTSase [19]. In the chemical conversion of dUMP to dTMP, a proton abstraction from C5 of dUMP (step 4 in Fig 1) takes place, and KIEs on this proton abstraction are a sensitive tool to investigate the order of substrate binding [19]. In these measurements, the substrate dUMP is labeled with either tritium at its C5 or $^{14}$C at its C2 (see Materials and Methods). For H/T observed KIEs (i.e., $k_{cat}/K_M$ for C5-protiated dUMP divided by $k_{cat}/K_M$ for C5-tritiated dUMP), a mixture of [5-$^3$H]-dUMP, [2-$^{14}$C, 5-$^1$H]-dUMP and unlabeled MTHF is used. In a strictly ordered binding mechanism as in ecTSase, where dUMP is the first to bind, a high concentration of the second-binding ligand, MTHF, obstructs the isotopic differentiation by the protein because of the commitment of the ternary complex to go forward [19, 29]. Thus, in an ordered binding mechanism, a high MTHF concentration causes the observed KIE for proton abstraction to approach unity as described in detail in refs [19] and [22].

However, in the scenario where the binding preference for the ligands is less strict, both substrates can dissociate from the ternary complex, reducing the commitment factor and yielding a non-unity KIE even at high concentration of MTHF. KIEs on the proton abstraction with hsTSase at MTHF concentrations ranging from 3 μM to 1000 μM indicate that high MTHF concentrations yielded a non-unity KIE, in contrast to a unity KIE for ecTSase (Fig 3).
The non-unity KIE (1.10 ± 0.02) suggests that \( hsTSase \) exhibits a slightly less ordered binding than \( ecTSase \). It should be noted that most mutations in \( ecTSase \) studied cause a disruption in the native ordered-binding mechanism [19, 21].

**Activation of hydride transfer in E. coli vs. human TSase.** In the cascade of chemical transformations catalyzed by TSase, the hydride transfer from the C6 of THF to the C7 of exocyclic methylene intermediate is particularly notable (step 5, Fig 1). A covalent bond between a carbon and hydrogen (C-H) is very strong and stable. Nevertheless, enzymes are capable of efficiently catalyzing the transfer of a hydride between carbons—reactions that do not occur readily in aqueous solution in the absence of the enzyme. Temperature dependence of intrinsic KIEs has proven to be a useful tool to probe the underlying physical and molecular details of a H-transfer in enzyme-catalyzed reactions [38, 41]. The temperature dependence of intrinsic KIEs reflects how tight and accurate the transition state (TS) of the H-transfer in question is. WT \( ecTSase \), like many other native enzymes, exhibits temperature-independent intrinsic KIEs for its catalyzed hydride transfer. According to the activated tunneling model, which has been described in detail in several review articles by us [32, 37, 38, 42] and others [41, 43–49], temperature-independent KIEs represents a very tight, well-organized TS for the H-transfer under study with a narrow distribution of distances between the H-donor and the H-acceptor (DADs) or, in other words, a high-frequency ‘vibration’ representing DAD sampling. On the other hand, temperature-dependent KIEs indicate a loosely-held TS with low-frequency of DAD sampling fluctuations. Most WT enzymes including \( ecTSase \) evolved to efficiently catalyze the hydride transfer by perfecting the TS structure for a difficult step [38]. However, perturbation of TS by mutating residues associated with the H-transfer reaction coordinate or using non-physiological/native substrates causes a broader distribution of DADs, which is reflected as temperature-dependent KIEs.

To probe the activation of the hydride transfer in \( hsTSase \), we measured KIEs at temperatures ranging from 5 to 35 °C by a competitive method that reports on the second order rate constant \( (k_{cat}/K_m) \). The observed KIEs are often suppressed by kinetic complexity [39, 50, 51] and therefore are smaller than the actual intrinsic KIEs on bond cleavage *per se*. To assess intrinsic KIEs, a combination of KIEs was measured (see Materials and Methods) and the Northrop method was used [50–52]. Intrinsic KIEs (KIE\(_{int}\)) for \( ecTSase \) (blue) and \( hsTSase \) (red) are shown in Fig 4 as an Arrhenius plot. The Arrhenius equation (Eq 4) was fitted to the intrinsic KIEs, which yielded isotope effects on the activation energy (\( \Delta E_a(T-H) \)) and on the pre-exponential factor \( (A_H/A_T) \) (Table 3) where H and T denotes hydrogen and tritium, respectively.

Though Mg\(^{2+}\) has a marginal impact on the observed KIEs, it doesn’t appear to have an impact on the intrinsic KIEs of \( hsTSase \). Regardless of the presence of Mg\(^{2+}\), the intrinsic KIEs on the hydride transfer are temperature independent for \( ecTSase \) [8, 18], similar to the many other WT systems [53]. However, it seems that \( hsTSase \) KIEs exhibits a statistically significant temperature dependency of its intrinsic hydride transfer KIEs, with \( \Delta E_a(T-H) \) of 0.5 ± 0.1 kcal/mol. Additionally, the magnitude of intrinsic KIEs are larger for \( hsTSase \) than that of \( ecTSase \). According to the activated tunneling models [32, 37, 38, 42], the DAD sampling frequency of hydride transfer in \( hsTSase \) is lower and the average DAD is longer, both of which suggest a less accurate TS of hydride transfer for the recombinant \( hsTSase \). Human enzymes are highly evolved, and therefore transition states for difficult steps are expected to have been optimized for an efficient H-transfer. For instance, human dihydrofolate reductase that catalyzes a hydride transfer from NADPH to dihydrofolate was found to exhibit temperature independent KIEs with smaller intrinsic KIEs than its bacterial counterpart [54]. A possible reason for the less than perfect TS in the recombinant \( hsTSase \) is that it has been expressed in *E. coli* and thus lacks post-translational modifications. It is clear that physiologically, TSase is post-
Fig 4. Arrhenius plot of KIE$_{\text{in}}$s for hydride transfer. The lines are from regression to Eq 4 for ecTSase (blue) [8] and hsTSase (red).

https://doi.org/10.1371/journal.pone.0196506.g004
translationally modified in certain cell types and conditions. However, it is not out of the question that the evolutionary pressure is not actually toward increasing activity and hydride transfer efficiency. *E. coli* grows quickly and withstands mutations. Human cells divide slowly, and mutations impact their viability. Therefore, if too much thymidylate is produced, there could be an imbalance between dTTP and the other dNTPs. As a result, polymerase error rates could go up, causing mutations. Indeed, “genomic instability” and cell death have been reported as a result of this alteration in relative concentrations of the dNTPs [55, 56]. Therefore, a less active TSase will maintain the proper ratio between dNTPs and minimize mistakes by the DNA polymerases [55, 56]. Thereby, we suspect the temperature-dependent KIE outcome may stem from the fact that the recombinant enzymes used in the current studies may not be physiologically relevant or from the possible evolutionary pressure to avoid overproduction of thymidylate. Investigations of this sort on TSase of organisms that are evolutionarily between *E. coli* and human do not appear to have been published. Initiatives are underway to express this enzyme in mammalian cells to assess any posttranslational modifications and their impact.

**Activation of proton abstraction in *E. coli* vs human TSase.** To probe the activation of the proton abstraction in *hs* TSase, we also examined this step by measuring KIEs and their temperature dependence. The observed KIEs on the proton abstraction depend on the concentration of MTHF (Fig 3). Because of the large commitments at high concentration of MTHF, only 4 μM MTHF was used. We measured both H/T and D/T observed KIEs and extracted intrinsic KIEs by the Northrop method as reported for the *ec* TSase [22]. As can be seen in Fig 5 and Table 3, in contrast to the hydride transfer, the intrinsic KIEs on the proton abstraction for *ec*TSase are steeply temperature dependent, suggesting a loose transition state for the proton abstraction. Unlike the hydride transfer where a well-defined species is the hydride acceptor, a network of hydrogen bonded residues [29] including water acts as a proton acceptor. As discussed in more detail in ref [22], this can be understood as a step requiring less catalytic enhancement by the enzyme, and thus its TS need not be “perfect.” Indeed, at 1 M cysteine and pH ~8–9 in room temperature aqueous solution, there is exchange of the C5 position as a result of Michael addition by the thiolate [30]. For *hs*TSase, the intrinsic KIEs are less steeply temperature dependent than for *ec*TSase [22], suggesting a less loose transition state for the proton abstraction in the mammalian enzyme.

**Conclusions**

TSase is a highly conserved enzyme from bacterial to human sources. A significant portion of the primary sequence, tertiary structure, and chemical mechanisms also seem to have been conserved in most of the organisms encoding the *thyA* gene throughout the evolutionary spectrum. Since bacterial TSases are more accessible and easier to study than their human counterpart, a plethora of kinetic, structural and mechanistic studies have been performed on TSases from *E. coli* and *L. casei* [4]. Bacterial TSases has thus been used as a model system for drug design. Despite having high-level similarities in structure and functions, TSase appears to

| Hydride Transfer | Proton Abstraction |
|------------------|--------------------|
| *ec*             | *hs*               | *ec*     | *hs*     |
| ΔE_{A,T-H} (kcal/mol) | 0.2 ± 0.1 | 0.5 ± 0.1 | 8.0 ± 0.1 | 6.0 ± 0.4 |
| A_H/A_T          | 5.6 ± 1.8         | 2.2 ± 0.2 | 8.3 (± 1.3) · 10^{-6} | 3.6 (± 2.3) · 10^{-4} |

^a^ ref [8]  
^b^ ref [22]  

https://doi.org/10.1371/journal.pone.0196506.t003
possess some species-specific properties. Bacterial and mammalian cells contrast in the intracellular concentration of Mg$^{2+}$—the former carries a relatively higher level of Mg$^{2+}$ than the latter [57–59]. Previous kinetic studies indicated that Mg$^{2+}$ increases the reaction and hydride transfer rate for $\text{ecTSase}$ [8], but the current kinetic studies indicate that this is not the case for

---

Fig 5. Arrhenius plot of KIE$_\text{int}$ on the proton abstraction. [ecTSase data from [22]].

https://doi.org/10.1371/journal.pone.0196506.g005
hsTase. Mg$^{2+}$ also does not seem to have any significant effects on the binding of the substrates for hs TSase—to the extent that $K_m$ values can be judged to reflect binding. The rate enhancement by Mg$^{2+}$ could be crucial for bacterial organisms to provide dTMP for multiplication of cells. The differences in sensitivity to Mg$^{2+}$ may be exploited in designing antibiotic drugs with no toxicity. Specifically, substrates with an abrogation of the carboxylate(s) of the para-aminobenzoyl glutamate tail that serve as a handle for Mg$^{2+}$ binding [8] would be anticipated to preferentially impact bacterial TSase rather than human TSase. Namely, a methylene tetrahydrofolate (MTHF) derivative missing one of the carboxylates of the PABA tail will bind in the active site of both human and \textit{E. coli} TSase. The human TSase will be unaffected, but the bacterial TSase will be slowed down.

Bacterial and mammalian TSases also exhibit differences in other respects. While \textit{ec}TSase exerts sequential ordered substrate binding control (dUMP followed by MTHF), hsTSase seems to have more flexibility in the binding order of substrates. Differences are also observed in the activation of the hydride transfers between these two enzymes. The hydride transfer for \textit{ec}TSase showed temperature independent intrinsic KIEs, while hsTSase shows more temperature dependent intrinsic KIEs, suggesting the former possesses an optimized TS while the latter exhibits a looser TS. However, a less accurate TS for a difficult step was not anticipated from a highly evolved enzyme, raising suspicion regarding the physiological relevancy of hsTSase when expressed in an \textit{E. coli} host system. However, we must not rule out evolutionary pressure driving the enzyme catalytic efficiency and hydride transfer TS efficiency down in order to balance the nucleotide pools and avoid the misincorporation of nucleotides by polymerases. To increase the likelihood of incorporation of natural posttranslational modifications, efforts are underway to express the hs TSase in a mammalian cell line.

Supporting information

**S1 Fig. Initial velocities for hsTSase vs. [MTHF].** The experiment was performed at [dUMP] = 100 μM. See Materials and methods section for additional details. (TIF)

**S2 Fig. Initial velocities for hsTSase vs. [dUMP].** The experiment was performed at [MTHF] = 100 μM. See Materials and methods section for additional details. (TIF)

**S1 Table.** Observed KIEs related to Fig 3. (XLSX)

**S2 Table.** Observed and intrinsic KIEs related to Fig 4. (XLSX)

**S3 Table.** Observed and intrinsic KIEs related to Fig 5. (XLSX)

**S4 Table.** Steady-state rate measurements related to S1 and S2 Figs. (XLSX)

Author Contributions

**Conceptualization:** Zahidul Islam, Amnon Kohen.

**Formal analysis:** Zahidul Islam, Ilya Gurevic, Amnon Kohen.

**Funding acquisition:** Amnon Kohen.
Investigation: Zahidul Islam, Ilya Gurevic, Timothy S. Strutzenberg, Ananda K. Ghosh, Tasnia Iqbal, Amnon Kohen.

Methodology: Zahidul Islam, Ilya Gurevic, Ananda K. Ghosh, Amnon Kohen.

Project administration: Zahidul Islam, Amnon Kohen.

Resources: Amnon Kohen.

Supervision: Zahidul Islam, Amnon Kohen.

Validation: Zahidul Islam, Amnon Kohen.

Visualization: Zahidul Islam, Amnon Kohen.

Writing – original draft: Zahidul Islam.

Writing – review & editing: Zahidul Islam, Ilya Gurevic, Amnon Kohen.

References

1. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem. 1995; 64:721–62. https://doi.org/10.1146/annurev.bi.64.070195.003445 PMID: 7574499

2. Taddia L, Ferrari S, Marraccini C, Severi L, Ponterini G, D’Arca D, et al. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resist Updat. 2015; 23:20–54. https://doi.org/10.1016/j.drup.2015.10.003 PMID: 26690339

3. Rose MG, Farrell MP, Schnitz JC. Thymidylate synthase: A critical target for cancer chemotherapy. Clin Colorectal Cancer. 2002; 1(4):220–9. https://doi.org/10.3816/CCC.2002.n.003 PMID: 12450420

4. Finer-Moore JS, Santi DV, Stroud RM. Lessons and Conclusions from Dissecting the Mechanism of a Bisubstrate Enzyme: Thymidylate Synthase Mutagenesis, Function, and Structure. Biochemistry. 2003; 42(2):248–56. https://doi.org/10.1021/bi020599a PMID: 12525151

5. Costi MP, Tondi D, Rinaldi M, Barlocco D, Pecorari P, Soragni F, et al. Structure-based studies on species-specific inhibition of thymidylate synthase. Biochim Biophys Acta, Mol Basis Dis. 2002; 1587(2–3):206–14. https://doi.org/10.1016/S0925-4439(02)00083-2

6. Carosati E, Tochowicz A, Marveriti G, Guaitoli G, Benedetti P, Ferrari S, et al. Inhibitor of Ovarian Cancer Cells Growth by Virtual Screening: A New Thiadole Derivative Targeting Human Thymidylate Synthase. J Med Chem. 2012; 55(22):10272–6. https://doi.org/10.1021/jm300850v PMID: 23075414

7. Phan J, Koli S, Minor W, Dunlap RB, Berger SH, Leboda L. Human Thymidylate synthase is in the closed conformation when complexed with dUMP and Raltitrexed, an antifolate drug. Biochemistry. 2001; 40(7):1897–902. https://doi.org/10.1021/bi002413i PMID: 11329255

8. Wang Z, Sapienza PJ, Abeyesinghe T, Luzum C, Lee AL, Finer-Moore JS, et al. Mg2+ Binds to the Surface of Thymidylate Synthase and Affects Hydride Transfer at the Interior Active Site. Journal of the American Chemical Society. 2013; 135(20):7583–92. https://doi.org/10.1021/ja400761x PMID: 23611499

9. Hardy LW. Structural aspects of the inhibition and catalytic mechanism of thymidylate synthase. Acta Biochim Pol. 1995; 42(4):367–80. Epub 1995/01/01. PMID: 8852328.

10. Chu E, Koeller DM, Casey JL, Drake JA, Chabner BA, Elwood PC, et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proceedings of the National Academy of Sciences of the United States of America. 1991; 88(20):8977–81. PMC52634. PMID: 1924359

11. Liu J, Schmitz JC, Lin X, Tai N, Yan W, Farrell M, et al. Thymidylate synthase as a translational regulator of cellular gene expression. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease. 2002; 1587(2–3):174–82. http://dx.doi.org/10.1016/S0925-4439(02)00080-7.

12. Garg D, Beribisky AV, Ponterini G, Ligabue A, Marveriti G, Martello A, et al. Translational repression of thymidylate synthase by targeting its mRNA. Nucleic Acids Res. 2013; 41(7):4159–70. https://doi.org/10.1093/nar/gkt098 PMID: 23923353

13. Brunn ND, Garcia Sega E, Kao MB, Hermann T. Targeting a regulatory element in human thymidylate synthase mRNA. ChemBioChem. 2012; 13(18):2738–44. https://doi.org/10.1002/cbic.201200603 PMID: 23143777
14. Frączyk T, Ruman T, Wilk P, Palmowski P, Rogowska-Wrzesinska A, Cieśla J, et al. Properties of phosphorlylated thymidylate synthase. Biochimica et Biophysica Acta (BBA)—Proteins and Proteomics. 2015; 1854(12):1922–34. http://dx.doi.org/10.1016/j.bbabio.2015.08.007.

15. Pedersen-Lane J, Maley GF, Chu E, Maley F. High-Level Expression of Human Thymidylate Synthase. Protein Expression and Purification. 1997; 10(2):256–62. http://dx.doi.org/10.1006/prep.1997.0750. https://doi.org/10.1006/prep.1997.0750 PMID: 9226722

16. Ludwiczak J, Maj P, Wilk P, Frączyk T, Ruman T, Kierdasszuk B, et al. Phosphorylation of thymidylate synthase affects slow-binding inhibition by 5-fluoro-dUMP and N(4)-hydroxy-dCMP. Mol Biosyst. 2016; 12(4):1333–41. https://doi.org/10.1039/c6mb00026f PMID: 26916840

17. Jarmula A, Frączyk T, Cieplak P, Rode W. Mechanism of influence of phosphorylation on serine 124 on a decrease of catalytic activity of human thymidylate synthase. Bioorg Med Chem. 2010; 18(10):3361–70. https://doi.org/10.1016/j.bmc.2010.04.019 PMID: 20430630

18. Agrawal N, Hong B, Mihai C, Kohen A. Vibrationally Enhanced Hydrogen Tunneling in the Escherichia coli Thymidylate Synthase Catalyzed Reaction. Biochemistry. 2004; 43(7):1998–2006. https://doi.org/10.1021/bi036124g PMID: 14967040

19. Hong B, Maley F, Kohen A. Role of Y94 in Proton and Hydride Transfers Catalyzed by Thymidylate Synthase. Biochemistry. 2007; 46(49):14188–97. https://doi.org/10.1021/bi701363s PMID: 17999469

20. Islam Z, Strutzenberg TS, Guerevic I, Kohen A. Concerted versus Stepwise Mechanism in Thymidylate Synthase. J Am Chem Soc. 2014; 136(28):9850–3. https://doi.org/10.1021/ja504341g PMID: 24949852

21. Islam Z, Strutzenberg TS, Ghosh AK, Kohen A. Activation of Two Sequential H-transfers in the Thymidylate Synthase Catalyzed Reaction. ACS Catal. 2015; 5(10):6601–8. Epub 2015/11/18. https://doi.org/10.1021/acscatal.5b01332 PMID: 26576323; PubMed Central PMCID: PMCPMC4643671.

22. Wang Z, Kohen A. Thymidylate Synthase Catalyzed H-transfers: Two Chapters in One Tale. J Am Chem Soc. 2010; 132(28):9820–5. https://doi.org/10.1021/ja103010b PMID: 20575541

23. Evans GB, Furneaux RH, Lewandowicz A, Schramm VL, Tyler PC. Synthesis of Second-Generation Transition State Analogues of Human Purine Nucleoside Phosphorylase. Journal of Medicinal Chemistry. 2003; 46(24):5271–6. https://doi.org/10.1021/jm030052a PMID: 14613329

24. Lewandowicz A, Schramm VL. Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases. Biochemistry. 2004; 43(6):1458–68. https://doi.org/10.1021/bi0359123 PMID: 14769022

25. Agrawal N, Mihai C, Kohen A. Microscale synthesis of isotopically labeled R-[6-xH]N5,N10-methylene-5,6,7,8-tetrahydrofolate as a cofactor for thymidylate synthase. Analytical biochemistry. 2004; 328(1):44–50. Epub 2004/04/15. https://doi.org/10.1016/j.ab.2004.01.029 PMID: 15081906.

26. Wang Z, Abeyesinghe T, Finer-Moore JS, Stroud RM, Kohen A. A remote mutation affects the hydride transfer by disrupting concerted protein motions in thymidylate synthase. J Am Chem Soc. 2012; 134(42):17722–30. Epub 2012/10/05. https://doi.org/10.1021/ja307859m PMID: 23034004; PubMed Central PMCID: PMCPMC4940247.

27. Blakley RL, McDougall BM. The Biosynthesis of Thymidylic Acid: III. PURIFICATION OF THYMIDYLATE SYNTHETASE AND ITS SPECTROPHOTOMETRIC ASSAY. Journal of Biological Chemistry. 1962; 237(3):812–8.

28. Cook P, Cleland WW. Enzyme kinetics and mechanism: Garland Science; 2007.

29. Ghosh AK, Islam Z, Krueger J, Abeyesinghe T, Kohen A. The general base in the thymidylate synthase affects slow-binding inhibition by 5-fluoro-dUMP and N(4)-hydroxy-dCMP. Mol Biosyst. 2016; 13(4):1593–600. Epub 2016/02/12. https://doi.org/10.1039/c5mb00216d PMID: 26798115; PubMed Central PMCID: PMCPMC4931226.

30. Wataya Y, Hayatsu H, Kawazoe Y. Cysteine-catalyzed hydrogen isotope exchange at the 5 position of uridylic acid. Journal of the American Chemical Society. 1972; 94(25):8927–8. https://doi.org/10.1021/ja00780a059 PMID: 4639922

31. Wang Z, Roston D, Kohen A. Chapter 6—Experimental and Theoretical Studies of Enzyme-Catalyzed Hydrogen-Transfer Reactions. In: Christov C, Karabeneche-Christova T, editors. Advances in Protein Chemistry and Structural Biology. 87: Academic Press; 2012. p. 155–80. https://doi.org/10.1016/B978-0-12-398312-1.00006-8

32. Roston D, Islam Z, Kohen A. Isotope Effects as Probes for Enzyme Catalyzed Hydrogen-Transfer Reactions. Molecules. 2013; 18(5):5543–67. https://doi.org/10.3390/molecules18055543 PMID: 23673528

33. Northrop DB. Intrinsic isotope effects in enzyme catalyzed reactions. Enzyme mechanism from isotope effects. 1991:181–202.

34. Birdsall DL, Finer-Moore J, Stroud RM. Entropy in Bi-substrate Enzymes: Proposed Role of an Alternate Site in Chaperoning Substrate into, and Products out of, Thymidylate Synthase. Journal of Molecular
Thymidylate synthase: Kinetics and functionality

35. Davisson VJ, Sirawaraporn W, Santi DV. Expression of human thymidylate synthase in Escherichia coli. Journal of Biological Chemistry. 1989; 264(16):9145–8. PMID: 2656995

36. Spencer HT, Villafranca JE, Appleman JR. Kinetic scheme for thymidylate synthase from Escherichia coli: determination from measurements of ligand binding, primary and secondary isotope effects, and pre-steady-state catalysis. Biochemistry. 1997; 36(14):4212–22. Epub 1997/04/08. https://doi.org/10.1021/bi961794q PMID: 9100016.

37. Klinman JP, Kohen A. Hydrogen Tunneling Links Protein Dynamics to Enzyme Catalysis Annu Rev Biochem. 2013; 82:5543–67.

38. Kohen A. Role of Dynamics in Enzyme Catalysis: Substantial versus Semantic Controversies. Acc Chem Res. 2015; 48(2):239–47. https://doi.org/10.1021/ar500322s PMID: 25539442

40. Stroud RM, Finer-Moore JS. Conformational Dynamics along an Enzymatic Reaction Pathway: Thymidylate Synthase, "the Movie". Biochemistry. 2003; 42(2):239–47. https://doi.org/10.1021/bi020598i PMID: 12525158

44. Marcus RA. H and Other Transfers in Enzymes and in Solution: Theory and Computations, a Unified View. 2. Applications to Experiment and Computations. J Phys Chem B. 2007; 111(Copyright © 2013 American Chemical Society (ACS). All Rights Reserved.):6643–54. https://doi.org/10.1021/jp071588s PMID: 17497918

55. Oliver FJ, Collins MKL, López-Rivas A. dNTP pools imbalance as a signal to initiate apoptosis. Experimental. 1996; 52(10):995–1000. https://doi.org/10.1007/bf01920108
56. Kumar D, Abdulovic AL, Viberg J, Nilsson AK, Kunkel TA, Chabes A. Mechanisms of mutagenesis in vivo due to imbalanced dNTP pools. Nucleic Acids Research. 2011; 39(4):1360–71. https://doi.org/10.1093/nar/gkq829 PMID: 20961955

57. Rink TJ, Tsien RY, Pozzan T. Cytoplasmic pH and free Mg2+ in lymphocytes. The Journal of Cell Biology. 1982; 95(1):189–96. https://doi.org/10.1083/jcb.95.1.189 PMID: 6815204

58. Alatossava T, Jütte H, Kuhn A, Kellenberger E. Manipulation of intracellular magnesium content in polymyxin B nonapeptide-sensitized Escherichia coli by ionophore A23187. Journal of Bacteriology. 1985; 162(1):413–9. PMID: 2984182

59. Kuhn A, Kellenberger E. Productive phage infection in Escherichia coli with reduced internal levels of the major cations. Journal of Bacteriology. 1985; 163(3):906–12. PMID: 3161872